Dear Colleagues,

One of the most challenging aspects in the treatment of high grade glioma (HGG) is the outcome assessment and the subsequent prognostic prevision. With the advancement of technical possibilities, it becomes fundamental to pursue a patient-tailored approach that takes into account a multitude of variables, including clinical, radiological, biomolecular and personal factors. This is particularly true for HGG patients that face the tremendous impact of such an aggressive tumor, as at each step of cure, a fundamental decision has to be made where every element is crucial. The most known example of a prognostic factor in HGG is the MGMT promoter methylation status and the response to alkylating agent chemotherapy, but many others are now under consideration in laboratory and clinical practice. From the first radiological evaluation to supportive end-of-life care, outcome assessment and prevision are of the utmost importance in HGG patient’s management to avoid both under or over treatments. This Special Issue will focus on the recent evidence on HGG’s Quoad vitam prognosis (prognostic radiological, clinical, biological, and genetical markers) and Quoad valetudinem prognosis (neurological and functional assessment of HGG patients, before and after therapy, including the psycho-social well-being of patients and caregivers).

Dr. Alba Scerrati
Dr. Giorgio Mantovani
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• high-grade glioma
• outcome assessment
• prognostic factors
• neuro-oncology
• glioblastoma